MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
23.95
+0.88
+3.81%
Opening 12:47 03/28 EDT
OPEN
23.18
PREV CLOSE
23.07
HIGH
24.19
LOW
22.71
VOLUME
367.94K
TURNOVER
0
52 WEEK HIGH
25.34
52 WEEK LOW
11.22
MARKET CAP
2.03B
P/E (TTM)
-8.0502
1D
5D
1M
3M
1Y
5Y
Syndax Pharmaceuticals Price Target Maintained With a $41.00/Share by HC Wainwright & Co.
Dow Jones · 2h ago
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
Benzinga · 2h ago
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
Syndax Pharmaceuticals has two lead molecules in line for FDA review: revumenib for the treatment of acute leukemia and axatilimab for chronic graft-versus-host disease. The company is a speculative buy for those willing to take a risk on the FDA approval process. The approval and launch ofrevumenib in 2024 and the axatillimab deal with Incyte are important milestones to watch.
Seeking Alpha · 4h ago
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Quanterix (QTRX)
TipRanks · 1d ago
Syndax Pharmaceuticals Price Target Maintained With a $41.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
Syndax Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
Benzinga · 1d ago
Syndax Announces FDA Priority Review Of NDA For Revumenib For Treatment Of R/R KMT2Ar Acute Leukemia
NASDAQ · 1d ago
More
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.